-transparent.png){kind=logo}
Sultopride and sulpiride are both chemically similar benzamide derivatives and selective antagonists of dopamine D2 receptors. However, these drugs differ in clinical properties. We compared the effects of sultopride and sulpiride on dopamine turnover in rats following the administration of these drugs alone or in combination with apomorphine. The administration of sultopride or sulpiride markedly accelerated dopamine turnover in the rat brain. The increase in the level of dopamine metabolites in the striatum was more marked in the sultopride-treated rats. Sulpiride affected the limbic dopamine receptors preferentially, whereas sultopride affected the striatal and the limbic dopamine receptors equally. A low dose of apomorphine induced a reduction in the concentration of dopamine metabolites in the striatum and the nucleus accumbens by approximately 55%, but not in the medial prefrontal cortex. Sultopride was more effective in preventing an apomorphine-induced reduction in dopamine metabolite levels. These results from rat experiments would model the pharmacological differences observed between sultopride and sulpiride in clinical use.
K Moriuchi, and
Y Imazu, and
H Yoneda
May 1989,
Neurochemical research,
K Moriuchi, and
Y Imazu, and
H Yoneda
January 1983,
Psychopharmacology,
K Moriuchi, and
Y Imazu, and
H Yoneda
November 1979,
British journal of pharmacology,
K Moriuchi, and
Y Imazu, and
H Yoneda
January 1988,
Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica,
K Moriuchi, and
Y Imazu, and
H Yoneda
October 1986,
European journal of pharmacology,
K Moriuchi, and
Y Imazu, and
H Yoneda
December 1981,
Archives internationales de pharmacodynamie et de therapie,
K Moriuchi, and
Y Imazu, and
H Yoneda
May 1979,
Journal of neurochemistry,
K Moriuchi, and
Y Imazu, and
H Yoneda
January 1975,
Therapie,
K Moriuchi, and
Y Imazu, and
H Yoneda
May 1981,
Experientia,
K Moriuchi, and
Y Imazu, and
H Yoneda
December 1981,
Neuropharmacology,
